保留射血分数心衰中个体化加速生理性起搏的临床结局:myPACE试验随访
该研究为myPACE随机临床试验的观察性延伸,纳入100例射血分数保留的心衰(HFpEF)且已植入生理性起搏器的患者,随访长达4年,比较个体化加速起搏与常规60次/分起搏的不良事件累积。意向性分析未达统计学显著性,符合方案分析显示个体化加速起搏与更慢的临床事件累积和更长无事件生存相关,主要由心衰相关事件驱动。
要点
- 意向性分析中个体化加速起搏与常规起搏的事件累积差异未达统计学显著。
- 符合方案分析中个体化加速起搏与更慢事件累积及更长无事件生存相关。
- 获益主要由心衰相关事件驱动,结果需更大规模多中心试验验证。
核心结论
- 意向性分析未显示个体化加速起搏与常规60次/分起搏在不良临床事件累积上存在统计学显著差异。
- 符合方案分析显示个体化加速生理性起搏与更慢的不良临床事件累积和更长的无事件生存相关。
- 上述结果主要由心衰相关事件驱动,属假设生成性质,需更大规模多中心试验确认。
研究设计与样本
- myPACE随机临床试验的观察性延伸,开放标签随访至多4年,共100例B期或C期HFpEF且已植入生理性起搏器的患者。
- 原试验随机分配至个体化加速起搏(myPACE)或60次/分常规起搏,本分析采用意向性分析和预设的符合方案分析。
主要发现
- 符合方案分析共87例维持指定心率设置(myPACE 39例 vs 常规48例),平均(SD)年龄74(10)岁,48例(55%)为男性。
- 符合方案分析结果主要由心衰相关事件驱动。
临床怎么用
- 对于已植入生理性起搏器的HFpEF患者,个体化加速起搏可能减少不良临床事件,但当前证据尚不足以常规推荐。
- 临床决策时应结合患者具体情况,并关注更大规模多中心试验的验证结果。
局限性
- 本研究为观察性延伸分析,样本量较小(共100例,符合方案分析87例)。
- 意向性分析未达统计学显著性,符合方案分析结果可能受选择偏倚影响。
- 结果为假设生成性质,需更大规模多中心试验确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with heart failure with preserved ejection fraction (HFpEF) and physiologic pacemakers may benefit from pacing rates above the standard 60 beats per minute (bpm). OBJECTIVE: To compare adverse event accrual between personalized accelerated pacing and usual care in HFpEF. DESIGN, SETTING, AND PARTICIPANTS: This was an observational extension of the myPACE randomized clinical trial with up to 4 years of follow-up in 100 patients with stage B or C HFpEF and preexisting physiologic pacemakers treated at the University of Vermont Medical Center. The myPACE study was conducted from June 2019 to December 2021; follow-up for this report was concluded in June 2023. INTERVENTION: Participants in the original myPACE trial were randomly assigned to either personalized accelerated pacing (myPACE) or 60 bpm (usual care). MAIN OUTCOMES AND MEASURES: The primary outcome was the accrual of first and recurrent adverse clinical events during the open-label follow-up phase-including urgent visits or hospitalizations for heart failure or atrial fibrillation, myocardial infarction, stroke, or death-assessed using an intention-to-treat (ITT) analysis and a prespecified per-protocol (PP) analysis of patients who continued their assigned treatment. Secondary outcomes included event-free survival in both ITT and PP analyses. RESULTS: Among the 100 original trial participants (48 in myPACE and 52 in usual care), the ITT analysis demonstrated a trend toward slower event accrual with the myPACE intervention (15 vs 33 events; Lin-Wei-Ying-Yang estimate [LWYY], 0.48; 95% CI, 0.22-1.06; P = .07) and longer event-free survival (hazard ratio [HR], 0.63; 95% CI, 0.31-1.29; P = .20) but did not reach statistical significance. In the prespecified PP analysis, 87 remained on their assigned heart rate setting over the 4-year follow-up (39 in myPACE and 48 in usual care). The mean (SD) age was 74 (10) years, and 48 participants (55%) were male. In this PP analysis, myPACE was associated with a slower accrual of clinical events (5 vs 31 events; LWYY, 0.16; 95% CI, 0.04-0.67; P = .01) and longer event-free survival (HR, 0.30; 95% CI, 0.11-0.80; P = .02) compared to usual care. These results were primarily driven by heart failure-related events. CONCLUSIONS AND RELEVANCE: In this observational clinical events analysis of the myPACE trial, analysis by ITT did not achieve statistical significance between study arms. However, PP analysis showed that personalized accelerated physiologic pacing was associated with a slower accrual of adverse clinical events compared with the standard 60-bpm setting. These results are hypothesis generating and warrant confirmation in larger multicenter trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04721314.
引用
- Infeld, Cyr, Novelli, et al. Clinical Outcomes With Personalized Accelerated Physiologic Pacing in Heart Failure With Preserved Ejection Fraction: Follow-up of the myPACE Trial. JAMA Cardiol. 2025. PMID: 40864451. doi:10.1001/jamacardio.2025.2827
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。